AVROBIO, INC. AVRO Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Sep'17	Jun'17
Operating expenses:
Research and development
60,802	54,974	50,564	46,754	41,894	35,095	0	0	0	0	0
General and administrative
23,896	20,835	18,488	16,466	14,261	11,148	0	0	0	0	0
Total operating expenses
84,698	75,809	69,052	63,220	56,155	46,243	0	0	0	0	0
Loss from operations
-84,698	-75,809	-69,052	-63,220	-56,155	-46,243	0	0	0	0	0
Other income (expense):
Interest income
2,909	2,934	2,835	2,556	2,225	1,726	0	0	0	0	0
Change in fair value of preferred stock warrant liability
-	-	0	-	-	162	0	0	0	0	-
Change in fair value of derivative liability
-	-	0	-	-	-1,629	0	0	0	0	0
Other expense
46	90	107	106	100	53	0	0	0	0	-
Total other income (expense), net
2,863	2,844	2,728	2,450	933	-118	0	0	0	0	0
Net loss
-81,835	-72,965	-66,324	-60,770	-55,222	-46,361	0	0	0	0	0
Comprehensive loss
-81,835	-72,965	-66,324	-60,770	-55,222	-46,361	0	0	0	0	0
Reconciliation of net loss to net loss attributable to common stockholders:
Net loss
-81,835	-72,965	-66,324	-60,770	-55,222	-46,361	0	0	0	0	0
Accretion of issuance costs on redeemable convertible preferred stock
-	-	-	-	-	2,243	0	0	0	-	-
Net loss attributable to common stockholders—basic and diluted
-	-	-66,324	-60,770	-	-48,604	0	0	0	0	0
Net loss per share attributable to common stockholders—basic and diluted (Note 10)
-0.77	-0.70	-0.57	-0.67	-0.72	4.36	-0.49	-2.98	-4.51	-2.85	-1.15
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders—basic and diluted
33,666	31,493	30,296	24,046	23,893	24,140	23,747	3,529	2,324	2,263	2,202